Literature DB >> 24702015

Is poorly differentiated thyroid cancer poorly characterized?

Kenneth D Burman1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24702015     DOI： 10.1210/jc.2014-1549

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  12 in total

1.  Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.

Authors:  Laura A Marlow; Stephen D Rohl; James L Miller; Jeffery A Knauf; James A Fagin; Mabel Ryder; Dragana Milosevic; Brian C Netzel; Stefan K Grebe; Honey V Reddi; Robert C Smallridge; John A Copland
Journal:  J Clin Endocrinol Metab       Date:  2018-09-01       Impact factor: 5.958

2.  Recognition of Key Genes in Human Anaplastic Thyroid Cancer via the Weighing Gene Coexpression Network.

Authors:  Yun Gong; Fanghua Xu; Lifei Deng; Lifen Peng
Journal:  Biomed Res Int       Date:  2022-06-23       Impact factor: 3.246

3.  Prognostic Impact of Histologic Grade for Papillary Thyroid Carcinoma.

Authors:  Allen S Ho; Michael Luu; Laurel Barrios; Bonnie L Balzer; Shikha Bose; Xuemo Fan; Evan Walgama; Jon Mallen-St Clair; Usman Alam; Iram Shafqat; De-Chen Lin; Yufei Chen; Jennifer E Van Eyk; Ellie G Maghami; Glenn D Braunstein; Wendy L Sacks; Zachary S Zumsteg
Journal:  Ann Surg Oncol       Date:  2020-08-17       Impact factor: 5.344

4.  Impact of Gender and Age on the Prognosis of Differentiated Thyroid Carcinoma: a Retrospective Analysis Based on SEER.

Authors:  Dan Zhang; Jianing Tang; Deguang Kong; Qiuxia Cui; Kun Wang; Yan Gong; Gaosong Wu
Journal:  Horm Cancer       Date:  2018-07-16       Impact factor: 3.869

Review 5.  Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.

Authors:  P Jiménez-Fonseca; J M Gómez Saez; J Santamaria Sandi; J Capdevila; E Navarro Gonzalez; C Zafon Llopis; T Ramón Y Cajal Asensio; G Riesco-Eizaguirre; E Grande; J C Galofré
Journal:  Clin Transl Oncol       Date:  2016-04-05       Impact factor: 3.405

Review 6.  Selective use of vandetanib in the treatment of thyroid cancer.

Authors:  Poupak Fallahi; Flavia Di Bari; Silvia Martina Ferrari; Roberto Spisni; Gabriele Materazzi; Paolo Miccoli; Salvatore Benvenga; Alessandro Antonelli
Journal:  Drug Des Devel Ther       Date:  2015-07-03       Impact factor: 4.162

Review 7.  New therapies for dedifferentiated papillary thyroid cancer.

Authors:  Poupak Fallahi; Valeria Mazzi; Roberto Vita; Silvia Martina Ferrari; Gabriele Materazzi; David Galleri; Salvatore Benvenga; Paolo Miccoli; Alessandro Antonelli
Journal:  Int J Mol Sci       Date:  2015-03-17       Impact factor: 5.923

8.  Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.

Authors:  Ying Wang; Zhigang Hu; Weiyuan Ma; Yong Niu; Jingwei Su; Lingxiang Zhang; Pengxin Zhao
Journal:  Invest New Drugs       Date:  2020-11-27       Impact factor: 3.850

Review 9.  Molecular Targeted Therapies of Aggressive Thyroid Cancer.

Authors:  Silvia Martina Ferrari; Poupak Fallahi; Ugo Politti; Gabriele Materazzi; Enke Baldini; Salvatore Ulisse; Paolo Miccoli; Alessandro Antonelli
Journal:  Front Endocrinol (Lausanne)       Date:  2015-11-20       Impact factor: 5.555

Review 10.  Therapeutic advances in anaplastic thyroid cancer: a current perspective.

Authors:  Shikha Saini; Kiara Tulla; Ajay V Maker; Kenneth D Burman; Bellur S Prabhakar
Journal:  Mol Cancer       Date:  2018-10-23       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.